Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more

Recent & Breaking News (NYSEAM:CVM)

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Business Wire November 7, 2024

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Business Wire October 22, 2024

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Business Wire October 1, 2024

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Business Wire September 16, 2024

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Business Wire September 10, 2024

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Business Wire September 4, 2024

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Business Wire August 15, 2024

CEL-SCI Announces Closing of $10.8 Million Offering

Business Wire July 29, 2024

CEL-SCI Announces Pricing of $10.8 Million Offering

Business Wire July 26, 2024

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Business Wire July 26, 2024

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Business Wire July 8, 2024

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Business Wire June 18, 2024

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Business Wire June 6, 2024

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

Business Wire May 16, 2024

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

Business Wire May 8, 2024

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Business Wire April 23, 2024

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Business Wire March 19, 2024

CEL-SCI Corporation Issues Letter to Shareholders

Business Wire March 6, 2024

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

Business Wire February 15, 2024

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

Business Wire February 13, 2024